Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
about
Hepatitis B Reactivation with Novel Agents in Non-Hodgkin's Lymphoma and Prevention StrategiesTargeting lymphoma with precision using semisynthetic anti-idiotype peptibodiesA Reduced-Intensity Conditioning Regimen for Patients with Dyskeratosis Congenita Undergoing Hematopoietic Stem Cell TransplantationOptimizing antiviral agents for hepatitis B management in malignant lymphomas.A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia.Therapeutic options and management of polyneuropathy associated with anti-MAG antibodies.Disseminated Mycobacterium tuberculosis following renal transplant with alemtuzumab induction.Invasive fungal infections in paediatric patients treated with macromolecular immunomodulators other than tumour necrosis alpha inhibitors.The HOVON68 CLL trial revisited: performance status and comorbidity affect survival in elderly patients with chronic lymphocytic leukemia.Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis.Relapsed Pulmonary Cryptococcosis during Tumor Necrosis Factor α Inhibitor TreatmentAcute hypoxemic respiratory failure in immunocompromised patients: the Efraim multinational prospective cohort study.Selective interaction of PEGylated polyglutamic acid nanocapsules with cancer cells in a 3D model of a metastatic lymph nodeHealthcare utilization and costs among patients with herpes zoster and solid tumor malignancy on chemotherapy: A retrospective cohort study.
P2860
Q26746486-C1200C17-2081-4D68-858C-123548C5F913Q35999110-4E5EA557-11BC-4877-A5C5-92ADD1F34221Q36782745-C1F33DBC-C1BE-44BC-A956-94CF2C59694EQ37666948-CFFE2A1C-5D8C-4894-A8F7-94111317FEFCQ38664705-C6CF4FB2-6FAA-421B-8E56-C299AB2480F4Q38856824-B5799485-6FD5-4B7E-8D66-7142C99AD24EQ39010415-4AD53D15-0053-4595-AE6B-40184978906AQ39264020-6E82DE30-4F0D-481A-A540-C9258F201D76Q39532967-51CF512D-2D15-4471-A199-8B1F6A5ED7DCQ40195372-54AC8E70-7430-407A-A4C0-FC94627999A0Q40511245-ABBCF6EE-B87B-446D-BC89-15EBA2929CB1Q41930205-7B636AE8-01FC-4AF0-834D-12F687E0F999Q42122391-D5A63A74-4B32-4C8D-B0E9-C31417593135Q47116736-8775AC3E-59D9-41E3-8675-D06F2CE247EA
P2860
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
@en
type
label
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
@en
prefLabel
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
@en
P2860
P356
P1476
Immunosuppression associated with novel chemotherapy agents and monoclonal antibodies.
@en
P2093
Vicki A Morrison
P2860
P304
P356
10.1093/CID/CIU592
P407
P478
59 Suppl 5
P577
2014-11-01T00:00:00Z